Redeye: Stille - Still(e) an Attractive Long-Term Case
Redeye retains its positive long-term view of Stille following its year-end report, which came in largely in line with our expectations on all levels except EBIT, which was notably lower. As S&T becomes more integrated into the business, synergies can be realized, and we have already seen the first initiatives of this going into 2022. We make minor adjustments to our estimates on the back of the report and increase our Base Case slightly.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/